생체 전기 의학 시장 규모는 예측 기간 동안 6.53%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다.
생체 전기 의학 산업은 세계적인 만성질환의 유병률 상승과 진입사업자의 전략적 이니셔티브 증가에 의해 견인되고 있습니다. 세계보건기구에 따르면 2019년에는 1,800만 명이 류마티스 관절염을 앓고 있으며, 그 70%가 여성이고 55%가 55세 이상으로 되어 있습니다. 또한 Crohn's & Colitis UK는 2022년까지 영국 123명 중 1명이 크론병 또는 궤양성 대장염을 앓고 있다고 추정합니다. 고비용 생체 전기 의학 기기가 시장 성장을 방해할 우려가 있지만, 그럼에도 불구하고 진입기업의 임상시험 확대와 투자 증가가 업계에 유익한 전망을 가져올 것으로 기대되고 있습니다.
지역별 인사이트
북미 시장은 2022년에 38.01%에서 가장 큰 시장 점유율을 차지했으며, 예측 기간 중에는 4.71%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 2030년에는 약 160억 달러 규모에 달할 것으로 예측됩니다. 또한 아시아태평양은 예측 기간 동안 CAGR 8.99%에서 가장 높은 성장률을 보일 것으로 예상됩니다.
북미의 생체 전기 의학 시장의 미래는 여전히 밝고 지속적인 확대가 기대되고 있습니다. 의료 인프라에 대한 투자와 최신 의료 솔루션의 인지도 향상은 시장 성장을 더욱 촉진할 것으로 예상됩니다. 기존 기업과 신규 진출기업 모두 보다 나은 수술 결과에 대한 요구의 고조에 대응하기 위해 기술적 개선을 활용하여 이러한 가능성을 파악할 준비가 되어 있습니다.
유럽 시장은 기술 개선, 의료비 상승, 만성 질환 유병률 증가로 2위 시장 점유율을 차지했습니다. 게다가 독일의 생체 전기 의학 시장이 가장 큰 시장 점유율을 갖고 있으며, 프랑스의 생체 전기 의학 시장은 유럽에서 가장 빠르게 확대될 것으로 예측됩니다.
아시아태평양 시장은 환자 인구의 많음, 만성 질환의 유병률 증가 및 유리한 규제 정책에 따라 2023년에서 2032년 사이에 가장 빠르게 발전할 것으로 예측됩니다. 또, 대기업이 이 지역에 끊임없이 진출하고 있어 지역 시장의 성장을 가속시키고 있습니다. 중국이 가장 큰 점유율을 차지하고 인도는 가장 빠르게 성장하는 시장이 될 전망입니다.
이 보고서는 세계의 생체 전기 의학 시장을 조사했으며, 시장 정의 및 개요, 시장 성장에 대한 각종 영향요인 분석, 시장 규모 추이 및 예측, 각종 구분 및 지역별 분석, 경쟁 환경, 주요 기업 프로파일 등을 정리했습니다.
Global Bioelectric Medicine Market Research Report Information by Type (Implantable Electroceutical Devices and Non-invasive Electroceutical Devices), by Product (Implantable Cardioverter Defibrillators, Cardiac Pacemakers, Cochlear Implants, Spinal Cord Stimulators, Deep Brain Stimulators, Transcutaneous Electrical Nerve Stimulators, Sacral Nerve Stimulators, Vagus Nerve Stimulators, And Others), By Application (Arrhythmia, Pain Management, Sensorineural Hearing Loss, Epilepsy, And Others), By End User (Hospitals & Clinics, ASCs, and Others), By Region (North America, Europe, Asia-Pacific, and Rest of the World) - Forecast till 2030
The Bioelectric Medicine Market is expected to expand at a compound annual growth rate (CAGR) of 6.53% over the projected period. The Bioelectric Medicine industry is being driven by rising prevalence of chronic diseases around the world, as well as increased strategic initiatives by industry participants. According to the World Health Organization, 18 million individuals suffered from rheumatoid arthritis in 2019, with 70% of them being women and 55% being over the age of 55. Furthermore, Crohn's & Colitis UK estimated that one in every 123 persons in the UK will have Crohn's disease or ulcerative colitis by 2022. However, the high cost of bioelectric medical devices is projected to hinder global market growth. Nonetheless, expanding clinical trials for bioelectric medicine and increased investment in bioelectric medicine by market participants are expected to generate profitable prospects for the industry.
The increasing prevalence of chronic diseases around the world is considerably contributing to the expansion of bioelectric medicine. Chronic diseases, including chronic pain conditions, neurological disorders, inflammatory diseases, and metabolic disorders, place a significant strain on healthcare systems and have a negative influence on patients' quality of life. Traditional treatment approaches, such as medicines and surgery, may have limited success or carry concerns of side effects for some people. The increasing prevalence of disorders, together with bioelectric medicine's prospective applicability in these circumstances, is driving up demand for bioelectric medicine products. For example, deep brain stimulation (DBS) has been proven to be effective in treating Parkinson's disease symptoms by regulating aberrant neural activity. Similarly, neuromodulation devices such as vagus nerve stimulation (VNS) have showed efficacy in lowering seizure frequency in epilepsy patients. Furthermore, in February 2024, the World Health Organization stated that approximately 50 million individuals worldwide suffer from epilepsy, with nearly 80% living in low- and middle-income nations.
Market Segment insights
Product-wise, the global bioelectric medicine segment includes implantable cardioverter defibrillators, cardiac pacemakers, cochlear implants, spinal cord stimulators, deep brain stimulators, transcutaneous electrical nerve stimulators, sacral nerve stimulators, vagus nerve stimulators, and others.
The bioelectric medicine market is divided into two types: implanted electroceutical devices and noninvasive electroceutical devices.
The Bioelectric Medicine Market has been categorized by application, including arrhythmia, pain management, sensorineural hearing loss, Parkinson's disease, tremor, depression, epilepsy, urine and fecal incontinence, among others.
The market is divided into three segments based on the end user: hospitals, research institutes, and others.
Regional insights
The study divides the market into four regions: North America, Europe, Asia-Pacific, and the rest of the world. North America's bioelectric medicine market held the greatest market share of 38.01% in 2022 and is expected to reach roughly USD 16.00 billion by 2030, growing at a 4.71% CAGR during the forecast period. However, Asia-Pacific is expected to develop at the fastest CAGR of 8.99% over the forecast period.
The future for the North American bioelectric medicine market remains positive, with continued expansion expected. Investments in healthcare infrastructure and increased awareness of modern medical solutions are projected to propel market growth even further. Both established firms and new entrants are ready to seize these possibilities, utilizing technological improvements to address the growing need for better surgical outcomes.
Europe's bioelectric medicine market accounted for the second-largest market share due to technological improvements, rising healthcare costs, and an increase in the prevalence of chronic conditions. Furthermore, the Germany bioelectric medicine market is expected to have the greatest market share, with France's bioelectric medicine market forecast to be the fastest expanding market in Europe.
The Asia-Pacific bioelectric medicine market is predicted to develop the fastest between 2023 and 2032 due to its large patient population, increased prevalence of chronic diseases, and favorable regulatory policies. Furthermore, prominent market companies are constantly expanding into this region, accelerating regional market growth. Furthermore, China's bioelectric medicine market held the greatest market share, while India's bioelectric medicine market is expected to be the fastest expanding market in the Asia-Pacific region.
Abbott (US), Boston Scientific Corporation (US), Bortnick (Germany), Aleva Neurotherapeutics (Switzerland), Cochlear Ltd. (Australia), LivaNova PLC (UK), Medtronic (Ireland), Charco Neurotech (UK), ElectroCore, Inc. (US), and Nevro Corp (US) are some of the key companies in the Bioelectric Medicine market.